LOS ANGELES, CA / ACCESSWIRE / August 8, 2017 / Lundin Law PC, a shareholder rights firm, announces a class action lawsuit against Sinovac Biotech Ltd. ("Sinovac" or the "Company") (NASDAQ: SVA) for possible violations of federal securities laws from April 30, 2013 through May 16, 2017, inclusive (the "Class Period"). Investors, who purchased or otherwise acquired Sinovac shares during the Class Period should contact the firm prior to the September 1, 2017 lead plaintiff motion deadline.
To participate in this class action lawsuit, click here.
You can also call Brian Lundin, Esq., of Lundin Law PC, at 888-713-1033, or you can e-mail him at email@example.com.
No class has been certified in the above action yet, and until a class is certified, you are not considered to be represented by an attorney. You may also choose to do nothing and be an absent class member.
According to the Complaint, throughout the Class Period, Sinovac made false and/or misleading statements and/or failed to disclose: that Chairman and CEO, Weidong Yin, bribed a member of the Chinese Food and Drug Administration to assist Sinovac's vaccine clinical trial and approval; that this conduct would subject the Company to heightened regulatory scrutiny; and that, as a result of the above, Sinovac's public statements were materially false and misleading at all relevant times. When this news was announced, Sinovac's stock price fell materially, which caused investors harm according to the Complaint.
Lundin Law PC was established by Brian Lundin, a securities litigator based in Los Angeles dedicated to upholding the rights of shareholders.
This press release may be considered Attorney Advertising in certain jurisdictions under the applicable law and ethics rules.
Lundin Law PC
Brian Lundin, Esq.
SOURCE: Lundin Law PC